Aura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have been given a consensus rating of "Buy" by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $23.00.

Several research analysts have weighed in on AURA shares. Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th.

Insider Activity

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 23,045 shares of company stock valued at $177,242. 5.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC purchased a new position in Aura Biosciences in the fourth quarter worth approximately $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Aura Biosciences by 27.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company's stock worth $1,122,000 after purchasing an additional 29,618 shares in the last quarter. Ensign Peak Advisors Inc raised its holdings in Aura Biosciences by 43.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company's stock worth $3,212,000 after purchasing an additional 118,000 shares in the last quarter. Deutsche Bank AG raised its holdings in Aura Biosciences by 56.7% during the fourth quarter. Deutsche Bank AG now owns 44,085 shares of the company's stock worth $362,000 after purchasing an additional 15,951 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Aura Biosciences by 20.5% during the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company's stock worth $422,000 after purchasing an additional 8,709 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company's stock.

Aura Biosciences Trading Down 0.9 %

Aura Biosciences stock traded down $0.07 during midday trading on Thursday, hitting $7.57. 91,340 shares of the stock were exchanged, compared to its average volume of 137,246. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The stock has a market capitalization of $377.87 million, a price-to-earnings ratio of -4.37 and a beta of 0.29. The stock's 50-day simple moving average is $8.01 and its 200 day simple moving average is $8.74.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.